Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

ROBERT JONES

Professor

Cardiff University

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

50%

Pharmacology

50%

Targeted Therapy

40%

Oncology

30%

Adjuvant Therapy

20%

Cancer Metabolism

20%

Drug Development

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles10

Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial

Article Link

Year:

2025

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer

Article Link

Year:

2025

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Article Link

Year:

2023

A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.

Article Link

Year:

2022

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

Article Link

Year:

2022

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Article Link

Year:

2022

Inhibition of WEE1 Is Effective in <i>TP53</i>- and <i>RAS</i>-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.

Article Link

Year:

2021

A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling.

Article Link

Year:

2021

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.

Article Link

Year:

2020

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer

Article Link

Year:

2020

Collaborators10

Patricia Roxburgh

University of Glasgow

UNITED KINGDOM

David J. Fisher

UNITED KINGDOM

Louise Carter

Clinical Senior Lecturer

The University of Manchester

UNITED KINGDOM

Rebecca S. Kristeleit

University of Arizona College of Medicine

UNITED STATES

Debashis Sarker

King’s College London

UNITED KINGDOM

Ruth Plummer

Clinical Professor

Newcastle University

UNITED KINGDOM

Richard Wilson

Professor of GI Oncology

University of Glasgow

UNITED KINGDOM

Elena Garralda

SPAIN

Angela Casbard

UNITED KINGDOM

Zsolt Horváth

Head of Department

Bács-Kiskun County Hospital

HUNGARY

How do I reach out?

Meet Kite AI